GSK gets court to block patent rules

Score one for GlaxoSmithKline. The company won an injunction against the U.S. Patent and Trademark Office, successfully blocking implementation of new rules governing patent continuances, at least temporarily.

GSK will now ask the court to permanently scrap the rules, which were set to go into effect today. The rules would have reduced the number of times a patent holder could dicker with rejected or pending patent, and GSK claimed they would hamstring innovation.

- read the report from Interactive Investor
- see this WSJ item

Related Articles:
GSK sues over new patent rules. Report
Standards on biotech patents get tougher. Report
Behind the scenes of GSK's overhaul. Report
GSK plant closure begins 5,000 job cuts. Report
Glaxo to cut $1.4B on falling sales. Report

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

The role of distributors like AmerisourceBergen, is to ensure patients can get access to therapies, no matter where they present.